2022-501759-95-00已完成2 期
An exploratory, prospective, multicenter, randomized, double blind, placebo + sham device controlled, study to assess the safety, usability, and initial efficacy of the ViXe combination for intravesical administration of XEOMIN® in the treatment of female patients with idiopathic overactive bladder (OAB).
Vensica Medical Ltd.8 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年3月23日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 8
- 主要终点
- Safety: Incidence of drug and device related adverse events from treatment to 12-weeks post treatment.
研究概览
简要总结
To demonstrate the Safety of ViXe combination and to investigate the usability, ease of use and patient satisfaction of the Vibe System and receive structured feedback from physician and patient.
研究设计
- 分配方式
- Randomized
- 主要目的
- Overall trial
- 盲法
- Double (Subject, Investigator)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female aged between 18 and 80 years at the time of signing the informed consent.
- •Females with childbearing potential must have a negative pregnancy test and must practice an acceptable method of birth control, from at least 4 weeks before treatment until 12 weeks after treatment.
- •Signed written informed consent.
- •Diagnosis of OAB for at least 6 months prior to screening, determined by documented subject history.
- •At least 8 voiding episodes/day based on 3-consecutive days voiding diary at screening.
- •OAB with at least 6 leaking episodes associated with urgency (UUI), demonstrated on 3-consecutive days voiding diary, and at least one episode per day.
- •Subject is mentally competent with the ability to understand and comply with the requirements of the study.
- •Subject is willing and able to initiate self-catheterization post treatment, if required.
- •Subject with inadequate response to conservative medication treatment/s as defined by the investigator.
- •Subject agrees to attend all follow-up evaluations and is willing and capable to fill out voiding diaries and questionnaires completely and accurately and is willing to complete required exams and tests.
排除标准
- •Previous participation in another study with any investigational drug or device within the past 90 days.
- •Subject with PVR ≥ 200 ml based on bladder ultrasound at screening visit.
- •Current or recurrent urinary tract infection (3 or more infections in the last 6 months), or presence of urinary fistula per physical examination, or known significant urinary tract obstruction or urethral stricture.
- •Subject who received botulinum toxin injections within the past 8 months for any indication and in any body part.
- •Subject with predominant stress incontinence based on MESA incontinence score and/or voiding diary at screening.
- •BMI ≥ 35 kg/m
- •If used should be on stable doses of diuretics for the past 3 months.
- •Subjects who have any implanted electronic devices (a pacemaker, for example), permanent or transient, that cannot be removed prior to the treatment.
- •Subjects who have received tibial or sacral nerve stimulation (SNS) anytime in the past or percutaneous tibial nerve (PTNS) in the last 3 months.
- •Previous urinary incontinence surgery or prolapse surgery or de novo urinary incontinence post-surgery within the last 12 months.
- •Any spinal surgery within the last 12 months.
- •Allergy to Botulinum neurotoxin type A or any of the other ingredients and components of this device or the drug
- •Previous abdominoperineal resection of the rectum or previous radical hysterectomy.
- •Diagnosis of interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines.
- •History of evidence of anatomic pelvic, urological or urogenital abnormality according to investigator’s discretion.
- •If used, subjects should be on stable dose of antimuscarinics and/or beta-3 adrenergic agonists for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12-weeks follow-up visit.
- •If used, subjects should be on a stable dose of tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12 weeks follow-up visit.
- •Subject with abnormal renal function defined by estimated glomerular filtration rate (eGFR) of 30 ml/min or less.
- •History of pelvic radiotherapy or chemotherapy for pelvic malignancies.
- •Diabetes with peripheral nerve neuropathy or severe uncontrolled diabetes (with HbA1C > 7.5%).
- •Uterine prolapse, cystocele, enterocele or rectocele past the hymen.
- •Deemed unsuitable for enrollment by the investigator based on history or physical examination.
- •Subject with OAB caused by neurological conditions (i.e., Myasthenia Gravis, ALS, Eaton-Lambert Syndrome, etc.)
- •Any psychiatric or personality disorder at the discretion of the study physician.
- •Any severe or uncontrolled systemic disease (e.g., cardiac, renal, pulmonary, hepatic, or gastrointestinal), malignant tumor, or medical history of HIV infection, or any findings from laboratory or physical examination performed at screening at the discretion of the investigator
- •Subject is breastfeeding.
- •Drug or alcohol abuse
- •Any neurological disease or disorder including Alzheimer’s, Parkinson, MS, stroke (CVA), neuropathy or injury resulting in neuropathy.
- •Subject currently under treatment with biofeedback, pelvic muscle rehabilitation, pelvic floor physical therapy. If willing to discontinue will be allowed to participate after 4 weeks of wash out. Self-Kegels exercises are allowed.
- •Bleeding disorders or treatment with anticoagulants, antiplatelet (except acetylsalicylic acid), or thrombolytic medications within 14 days prior to screening.
- •Subjects with compromised respiratory function or dysphagia.
- •Current or planned treatment with drugs that interfere with neuromuscular transmission (e.g., aminoglycoside, polypeptide antibiotics, lincomycin antibiotics, or aminoquinolines)
- •Subject with known polyuria/polydipsia with 24-hour total volume void > 3000 ml.
结局指标
主要结局
Safety: Incidence of drug and device related adverse events from treatment to 12-weeks post treatment.
Safety: Incidence of drug and device related adverse events from treatment to 12-weeks post treatment.
Usability: Physician, Subject and Technician’s questionnaires.
Usability: Physician, Subject and Technician’s questionnaires.
次要结局
- Mean change from baseline in the average number of daily Urgency Urinary Incontinence (UUI) Episodes at 6 and 12-weeks post treatment based on a 3-day voiding diary.
- Mean change from Baseline in the average number of daily voiding episodes at 6 and 12-weeks post treatment based on a 3-day voiding diary.
- Mean Change from baseline in Urinary grade 3 or 4 Urgency Episodes at 6 and 12-weeks post treatment based on a 3-day voiding diary.
- Mean change from baseline in Number of large leaks at 6 and 12- weeks post treatment based on a 3-day voiding diary.
- Change from baseline in QAB-q total score at week 12.
- Mean change from baseline in the average number of daily Nocturia episodes at 6 and 12-weeks post treatment based on a 3-day voiding diary.
研究者
Avner Geva
Scientific
Vensica Medical Ltd.
研究点 (8)
Loading locations...
相似试验
招募中
2 期
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease DementiaNCT07284472Exciva GmbH300
招募中
1 期
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal DegenerationRetinal DegenerationNCT07269665Axovia Therapeutics12
已完成
2 期
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCystic FibrosisNCT03912233Vertex Pharmaceuticals Incorporated87
招募中
3 期
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial2022-501522-38-00Abbvie Deutschland GmbH & Co. KG29
尚未招募
3 期
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 YearsRabiesNCT07275645Ab&B Bio-tech Co., Ltd.JS3,000